Using an MDA-MB-231 orthotopic breast cancer model, we found that the combination of the GPx4 inhibitor RSL3 and system xc− inhibitor sorafenib resulted in the strongest inhibition of tumor growth and lowest tumor weight (Fig. 8a, b). Here, GPX4 is linked to breast cancer.